Literature DB >> 17279610

Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer.

Nicholas C Souders1, Duane A Sewell, Zhen-Kun Pan, S Farzana Hussain, Alexander Rodriguez, Anu Wallecha, Yvonne Paterson.   

Abstract

We have created a transgenic mouse with tissue-specific expression of the human papilloma virus (HPV) 16 E6 and E7 oncoproteins in the thyroid as a model of HPV transformed cancer. The expression of the transgenes results in the formation of palpable thyroid tumors. E7 is not expressed in other tissues but is expressed in medullary thymic epithelial cells, which have been implicated in the control of negative selection. We show that Listeria-based vaccines against E7 can induce the regression of solid implanted tumors in the transgenic mice, although at a lower frequency than in wild type (WT) mice. E7-specific CD8+ T cells induced in transgenic mice are of both lower avidity and lower frequency when compared to the WT mice. In this model, Listeria-based vaccines against E7 appear to be overcoming central tolerance by expanding low avidity CD8+ T cells specific for E7 that are not deleted during thymopoesis and can eliminate solid tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17279610      PMCID: PMC3077294     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  42 in total

1.  A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity.

Authors:  A L Decatur; D A Portnoy
Journal:  Science       Date:  2000-11-03       Impact factor: 47.728

Review 2.  PEST sequences and regulation by proteolysis.

Authors:  M Rechsteiner; S W Rogers
Journal:  Trends Biochem Sci       Date:  1996-07       Impact factor: 13.807

3.  Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.

Authors:  Reshma Singh; Mary E Dominiecki; Elizabeth M Jaffee; Yvonne Paterson
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

Review 4.  Antigen recognition and T-cell biology.

Authors:  Michael I Nishimura; Jeffrey J Roszkowski; Tamson V Moore; Natasha Brasic; Mark D McKee; Timothy M Clay
Journal:  Cancer Treat Res       Date:  2005

5.  E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein.

Authors:  K Herd; G J Fernando; L A Dunn; I H Frazer; P Lambert; R W Tindle
Journal:  Virology       Date:  1997-04-28       Impact factor: 3.616

6.  Nonspecific down-regulation of CD8+ T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter.

Authors:  R W Tindle; K Herd; T Doan; G Bryson; G R Leggatt; P Lambert; I H Frazer; M Street
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.

Authors:  M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

8.  Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.

Authors:  A Riezebos-Brilman; J Regts; E-J Freyschmidt; B Dontje; J Wilschut; T Daemen
Journal:  Gene Ther       Date:  2005-09       Impact factor: 5.250

9.  Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8alphabeta versus CD8alphaalpha expression.

Authors:  A G Cawthon; H Lu; M A Alexander-Miller
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

10.  Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16.

Authors:  I Melero; M C Singhal; P McGowan; H S Haugen; J Blake; K E Hellstrom; G Yang; C H Clegg; L Chen
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

View more
  37 in total

1.  In vivo modulation of avidity in highly sensitive CD8(+) effector T cells following viral infection.

Authors:  Beth C Holbrook; Rama D Yammani; Lance K Blevins; Martha A Alexander-Miller
Journal:  Viral Immunol       Date:  2013-08-24       Impact factor: 2.257

2.  Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy.

Authors:  Laurence M Wood; Zhen-Kun Pan; Vafa Shahabi; Yvonne Paterson
Journal:  Cancer Immunol Immunother       Date:  2010-03-06       Impact factor: 6.968

3.  Targeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials.

Authors:  Jean-Luc Brun; José Rajaonarison; Nicolas Nocart; Laura Hoarau; Stéphanie Brun; Isabelle Garrigue
Journal:  Mol Clin Oncol       Date:  2017-12-08

Review 4.  Emerging human papillomavirus vaccines.

Authors:  Barbara Ma; Bharat Maraj; Nam Phuong Tran; Jayne Knoff; Alexander Chen; Ronald D Alvarez; Chien-Fu Hung; T-C Wu
Journal:  Expert Opin Emerg Drugs       Date:  2012-11-19       Impact factor: 4.191

5.  Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.

Authors:  Kent A Smith; Brenna L Meisenburg; Victor L Tam; Robb R Pagarigan; Raymond Wong; Diljeet K Joea; Liz Lantzy; Mayra A Carrillo; Todd M Gross; Uriel M Malyankar; Chih-Sheng Chiang; Diane M Da Silva; Thomas M Kündig; W Martin Kast; Zhiyong Qiu; Adrian Bot
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

Review 6.  Therapeutic human papillomavirus vaccines: current clinical trials and future directions.

Authors:  Chien-Fu Hung; Barbara Ma; Archana Monie; Shaw-Wei Tsen; T-C Wu
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

7.  Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting.

Authors:  Matthew M Seavey; Yvonne Paterson
Journal:  Breast Cancer (Dove Med Press)       Date:  2009-10-05

Review 8.  Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

Authors:  Shreya Kanodia; Diane M Da Silva; W Martin Kast
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

9.  Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors.

Authors:  Duane A Sewell; Zhen Kun Pan; Yvonne Paterson
Journal:  Vaccine       Date:  2008-08-03       Impact factor: 3.641

Review 10.  Progress and challenges in the vaccine-based treatment of head and neck cancers.

Authors:  Aldo Venuti
Journal:  J Exp Clin Cancer Res       Date:  2009-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.